Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
EVE Health Increases Capital Raising to $1.3m with $400,000 Cornerstone Investment
EVE Health Group lifts capital raise to $1.3m with $400k cornerstone, signalling reformulated-drug strategy and new science adviser amid Libbo launch.
Latest Stories
Orthocell's Remplir Device Used in 23 Ukrainian Soldier Surgeries, Validating Field Utility
Orthocell's Remplir validated after 23 Ukrainian surgeries, boosting defence-market traction and global expansion; HY26 revenue +49%, cash ~A$49m.
DorsaVi Advances Ultra Edge Platform with New Partnerships and Key Milestones
DorsaVi secures Ultra Edge boost: Dr Patel and SEROMA total A$200k in deals, validating on-device AI and advancing 22-nm RRAM progress.
Tetratherix Expands Tetramatrix Platform with Precision Medicine Franchise and US Partnership
Tetratherix launches precision medicine franchise via Tetramatrix; signs exclusive US$3m/year deal with Superpower Health for 10 years.
BlinkLab Completes Pivotal FDA Study Site Network Ahead of Q1 2026 Trial Start
BlinkLab completes 10-site pivotal FDA study network ahead of March 2026 start; pilot 83.7%/84.7%; 510(k) submission H2 CY2026.
Racura Oncology Advances Lung Cancer Program with HARNESS-1 Trial Approval
Racura Oncology wins HARNESS-1 Phase 1a/b governance approval for RC220/osimertinib in EGFR-mutant NSCLC, enabling site initiation and recruitment.
Immutep Discontinues TACTI-004 Phase III Trial Due to Futility
Immutep halts TACTI-004 Phase III in first-line NSCLC due to futility; shares resume trading as cash runway extends beyond Q2 CY2027.
EVE Health Group Raises $0.9m to Advance Reformulated Pharmaceutical Pipeline
EVE Health Group raises $0.904m via placement to push reformulated drug delivery pipeline, accelerating IP, regulatory work and licensing talks.
Patrys Advances RLS-2201 Program with Manufacturing Start and FDA Regulatory Engagement
Patrys kicks off RLS-2201 manufacturing with BioCina and FDA 505(b)(2) engagement, targeting Phase 0 trials in H2 2026.
Dimerix Completes Adult Dosing for ACTION3 DMX-200 Trial
Dimerix completes adult dosing for ACTION3 DMX-200 in FSGS; 333 patients vs 286 target, boosting statistical power and de-risking regulatory submission.
Orthocell Appoints Exclusive Remplir Distributor Ahead of UK Rollout
Orthocell names LEDA Orthopaedics exclusive UK distributor for Remplir ahead of regulatory approval, signaling rapid UK rollout and market prep.
EVE Health Advances Reformulated Drugs Targeting Sexual Health and Cardiovascular Markets
EVE Health advances reformulated ED/PE sprays and Apixaban delivery, expanding its sexual health and cardiovascular pipeline.